Details

Autor(en) / Beteiligte

• Matsuo, Koji
• Takazawa, Yutaka
• Ross, Malcolm S.
• Elishaev, Esther
• Yunokawa, Mayu
• Sheridan, Todd B.
• Bush, Stephen H.
• Klobocista, Merieme M.
• Blake, Erin A.
• Takano, Tadao
• Baba, Tsukasa
• Satoh, Shinya
• Shida, Masako
• Ikeda, Yuji
• Adachi, Sosuke
• Yokoyama, Takuhei
• Takekuma, Munetaka
• Yanai, Shiori
• Takeuchi, Satoshi
• Nishimura, Masato
• Iwasaki, Keita
• Johnson, Marian S.
• Yoshida, Masayuki
• Hakam, Ardeshir
• Machida, Hiroko
• Mhawech-Fauceglia, Paulette
• Ueda, Yutaka
• Yoshino, Kiyoshi
• Kajiwara, Hiroshi
• Hasegawa, Kosei
• Yasuda, Masanori
• Miyake, Takahito M.
• Moriya, Takuya
• Yuba, Yoshiaki
• Morgan, Terry
• Fukagawa, Tomoyuki
• Pejovic, Tanja
• Nagano, Tadayoshi
• Sasaki, Takeshi
• Richmond, Abby M.
• Post, Miriam D.
• Shahzad, Mian M. K.
• Im, Dwight D.
• Yoshida, Hiroshi
• Enomoto, Takayuki
• Omatsu, Kohei
• Ueland, Frederick R.
• Kelley, Joseph L.
• Karabakhtsian, Rouzan G.
• Roman, Lynda D.

Titel

Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma

Ist Teil von

• Annals of surgical oncology, 2018-09, Vol.25 (9), p.2756-2766

Ort / Verlag

Cham: Springer International Publishing

Erscheinungsjahr

2018

Quelle

MEDLINE

Beschreibungen/Notizen

• Objective The aim of this study was to examine the significance of lymphovascular space invasion (LVSI) with a sarcomatous component on the tumor characteristics and clinical outcomes of women with uterine carcinosarcoma (UCS). Methods This was a secondary analysis of a prior multicenter retrospective study that examined women with stage I–IV UCS who underwent primary hysterectomy. Archived histopathology slides were reviewed and LVSI was scored as follows: LVSI with a carcinomatous component alone (LVSI-carcinoma; n  = 375, 76.8%) or LVSI containing a sarcomatous component with or without a carcinomatous component (LVSI-sarcoma; n  = 113, 23.2%). Qualitative metrics of LVSI were correlated to clinicopathological factors and survival outcome. Results Tumors in the LVSI-sarcoma group were more likely to have sarcoma dominance (82.1 vs. 26.4%) heterologous sarcomatous component (51.3 vs. 37.9%), low-grade carcinoma (42.5 vs. 22.4%), and large tumor size (81.0 vs. 70.2%) in the primary tumor site compared with tumors in the LVSI-carcinoma group (all p  < 0.05). On multivariate analysis, LVSI-sarcoma was independently associated with decreased progression-free survival (5-year rates: 34.9 vs. 40.8%, adjusted hazard ratio [HR] 1.84, 95% confidence interval [CI] 1.36–2.50, p  < 0.001), and cause-specific survival (5-year rates: 41.8 vs. 55.9%, adjusted HR 1.95, 95% CI 1.39–2.75, p  < 0.001) compared with LVSI-carcinoma. Postoperative radiotherapy for women with LVSI-sarcoma had a higher reduction rate of recurrence/progression of disease (54% reduction, p  = 0.04) compared with postoperative radiotherapy for women with LVSI-carcinoma (26% reduction, p  = 0.08). Conclusion In UCS, the presence of a sarcomatous component in LVSI is particularly prevalent when a tumor has sarcoma dominance. Our study suggests that LVSI containing a sarcomatous component may be a predictor of decreased survival for women with UCS.